Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivelestat in Acute Lung Injury
NCT00036062Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2001
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of sivelestat in acute lung injury (ALI), acute respiratory distress syndrome (ARDS), sponsored by Eli Lilly and Company. Started Aug 2001; status: completed.
02
Drugs
sivelestat
03
Conditions
acute lung injury (ALI)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT00036062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036062.